化疗常引起恶心和呕吐,是病人和医生都十分关注的问题。枢复宁(ondansetron)为5-HT_3受体拮抗剂,已证实其静脉应用对控制化疗引起的呕吐安全有效。本文旨在评价口服枢复宁对于接受以环磷酰胺为主的门诊化疗病人的止吐效果和安全性。方法:1989年3月至1990年1月,对27个肿瘤中心的349例化疗病人在开始应用环磷酰胺(≥450mg/m~2)加氨甲喋呤(≥30mg/m~2)或阿霉素(≥35mg/m~2)化疗时双盲采用枢复宁作为防止呕吐的研究。患者被 Chemotherapy often causes nausea and vomiting. It is a matter of great concern to both patients and doctors. Ondansetron is a 5-HT3 receptor antagonist and its intravenous application has been shown to be safe and effective in controlling chemotherapy-induced emesis. The purpose of this article was to evaluate the antiemetic efficacy and safety of oral administration of shufuning for patients receiving cyclophosphamide-based outpatient chemotherapy. METHODS: From March 1989 to January 1990, 349 patients with chemotherapy in 27 cancer centers were started on cyclophosphamide (≥450 mg/m~2) plus methotrexate (≥30 mg/m~2) or adriamycin. (35mg/m~2) double-blind shufuning as anti-emesis study during chemotherapy. The patient was